WallStSmart

Fortress Biotech Inc (FBIO)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 873% more annual revenue ($606.42M vs $62.30M). FBIO leads profitability with a 6.4% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

FBIO

Hold

39

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 5.0

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FBIO2 strengths · Avg: 8.0/10
Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
20.5%8/10

Revenue surging 20.5% year-over-year

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

FBIO4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$98.08M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
6.4%3/10

6.4% margin — thin

Return on EquityProfitability
-2.1%2/10

ROE of -2.1% — below average capital efficiency

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : FBIO

The strongest argument for FBIO centers on Price/Book, Revenue Growth. Revenue growth of 20.5% demonstrates continued momentum.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : FBIO

The primary concerns for FBIO are EPS Growth, Market Cap, Profit Margin.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

FBIO profiles as a growth stock while INSM is a turnaround play — different risk/reward profiles.

FBIO carries more volatility with a beta of 1.41 — expect wider price swings.

FBIO is growing revenue faster at 20.5% — sustainability is the question.

FBIO generates stronger free cash flow (-6M), providing more financial flexibility.

Bottom Line

FBIO scores higher overall (39/100 vs 39/100) and 20.5% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fortress Biotech Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products. The company is headquartered in New York, New York.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?